BidaskClub upgraded shares of Atrion (NASDAQ:ATRI) from a hold rating to a buy rating in a research note published on Friday.

Shares of NASDAQ ATRI opened at $653.00 on Friday. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 34.99 and a beta of 0.64. Atrion has a 1 year low of $516.85 and a 1 year high of $694.25.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 28th. Stockholders of record on Friday, September 14th will be paid a dividend of $1.35 per share. This represents a $5.40 annualized dividend and a dividend yield of 0.83%. The ex-dividend date is Thursday, September 13th. This is an increase from Atrion’s previous quarterly dividend of $1.20.

Institutional investors have recently bought and sold shares of the company. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new stake in shares of Atrion during the second quarter valued at approximately $240,000. Xact Kapitalforvaltning AB bought a new stake in shares of Atrion during the first quarter valued at approximately $248,000. Principal Financial Group Inc. bought a new stake in shares of Atrion during the first quarter valued at approximately $249,000. Victory Capital Management Inc. raised its stake in shares of Atrion by 28.4% during the first quarter. Victory Capital Management Inc. now owns 438 shares of the medical instruments supplier’s stock valued at $277,000 after acquiring an additional 97 shares in the last quarter. Finally, Chevy Chase Trust Holdings Inc. bought a new stake in shares of Atrion during the second quarter valued at approximately $300,000. 61.98% of the stock is owned by hedge funds and other institutional investors.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Featured Story: Price to Earnings Ratio (PE)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.